Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations

Journal of Immunology

Volumn 180, Issue 6, 2008, Pages 4338-4345

  Peipp, Matthias ^a   Schneider Merck, Tanja ^a   Dechant, Michael ^a   Beyer, Thomas ^a   Van Bueren, Jeroen J Lammerts ^b   Bleeker, Wim K ^b   Parren, Paul W H I ^b   Van De Winkel, Jan G J ^c   Valerius, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b GENMAB   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ZALUTUMUMAB; CANCER ANTIBODY; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH INHIBITOR; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ACTIVITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; GENE MUTATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR CELL; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL DEATH; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG TUMOR; MOUSE; MUTATION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL DEATH; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH INHIBITORS; HUMANS; LUNG NEOPLASMS; MICE; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 44849086585     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.6.4338     Document Type: Article

References (50)

1. Reichert, J. M., and V. E. Valge-Archer. 2007. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 6: 349-356.
2. Houghton, A. N., and D. A. Scheinberg. 2000. Monoclonal antibody therapies: a "constant" threat to cancer. Nat. Med. 6: 373-374.
3. Baselga, J., and C. L. Arteaga. 2005. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 23: 2445-2459.
4. Krause, D. S., and R. A. Van Etten. 2005. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353: 172-187.
5. Mendelsohn, J., and J. Baselga. 2006. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 33: 369-385.
6. Shepherd, F. A., J. Rodrigues Pereira, T. Ciuleanu, E. H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, et al. 2005. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353: 123-132.
7. Thatcher, N., A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, J. von Pawel, S. Thongprasert, E. H. Tan, K. Pemberton, V. Archer, and K. Carroll. 2005. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet 366: 1527-1537.
8. Pao, W., and V. A. Miller. 2005. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23: 2556-2568.
9. Hirsch, F. R., M. Varella-Garcia, F. Cappuzzo, J. McCoy, L. Bemis, A. C. Xavier, R. Dziadziuszko, P. Gumerlock, K. Chansky, H. West, et al. 2007. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol. 18: 752-760.
10. Lynch, T. J., D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350: 2129-2139.
11. Pao, W., V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, et al. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101: 13306-13311.
12. Paez, J. G., P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
13. Han, S. W., T. Y. Kim, P. G. Hwang, S. Jeong, J. Kim, I. S. Choi, D. Y. Oh, J. H. Kim, D. W. Kim, D. H. Chung, et al. 2005. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23: 2493-2501.
14. Kobayashi, S., T. J. Boggon, T. Dayaram, P. A. Janne, O. Kocher, M. Meyerson, B. E. Johnson, M. J. Eck, D. G. Tenen, and B. Halmos. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352: 786-792.
15. Mulloy, R., A. Ferrand, Y. Kim, R. Sordella, D. W. Bell, D. A. Haber, K. S. Anderson, and J. Settleman. 2007. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 67: 2325-2330.
16. Carey, K. D., A. J. Garton, M. S. Romero, J. Kahler, S. Thomson, S. Ross, F. Park, J. D. Haley, N. Gibson, and M. X. Sliwkowski. 2006. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66: 8163-8171.
17. Kosaka, T., Y. Yatabe, H. Endoh, K. Yoshida, T. Hida, M. Tsuboi, H. Tada, H. Kuwano, and T. Mitsudomi. 2006. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 12: 5764-5769.
18. Pao, W., V. A. Miller, K. A. Politi, G. J. Riely, R. Somwar, M. F. Zakowski, M. G. Kris, and H. Varmus. 2005. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2: e73.
19. Eberhard, D. A., B. E. Johnson, L. C. Amler, A. D. Goddard, S. L. Heldens, R. S. Herbst, W. L. Ince, P. A. Janne, T. Januario, D. H. Johnson, et al. 2005. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23: 5900-5909.
20. Politi, K., M. F. Zakowski, P. D. Fan, E. A. Schonfeld, W. Pao, and H. E. Varmus. 2006. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20: 1496-1510.
21. Ji, H., D. Li, L. Chen, T. Shimamura, S. Kobayashi, K. McNamara, U. Mahmood, A. Mitchell, Y. Sun, R. Al-Hashem, et al. 2006. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9: 485-495.
22. Sordella, R., D. W. Bell, D. A. Haber, and J. Settleman. 2004. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
23. Carter, P. J. 2006. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6: 343-357.
24. Bowles, J. A., S. Y. Wang, B. K. Link, B. Allan, G. Beuerlein, M. A. Campbell, D. Marquis, B. Ondek, J. E. Wooldridge, B. J. Smith, et al. 2006. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108: 2648-2654.
25. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512.
26. Cragg, M. S., R. R. French, and M. J. Glennie. 1999. Signaling antibodies in cancer therapy. Curr. Opin. Immunol. 11: 541-547.
27. Tutt, A. L., R. R. French, T. M. Illidge, J. Honeychurch, H. M. McBride, C. A. Penfold, D. T. Fearon, R. M. Parkhouse, G. G. Klaus, and M. J. Glennie. 1998. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 161: 3176-3185.
28. Vuist, W. M., R. Levy, and D. G. Maloney. 1994. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 83: 899-906.
29. Mendelsohn, J. 1997. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 3: 2703-2707.
30. 1 arrest in prostatic cancer cell line DU145. Cancer Res. 56: 3666-3669.
31. Tiroch, K., B. Stockmeyer, C. Frank, and T. Valerius. 2002. Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity. J. Immunol. 168: 3275-3282.
32. Lilenbaum, R. C. 2006. The evolving role of cetuximab in non-small cell lung cancer. Clin. Cancer Res. 12: 4432s-4435s.
33. Bleeker, W. K., J. J. Lammerts van Bueren, H. H. van Ojik, A. F. Gerritsen, M. Pluyter, M. Houtkamp, E. Halk, J. Goldstein, J. Schuurman, M. A. van Dijk, et al. 2004. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J. Immunol. 173: 4699-4707.
34. Warmuth, M., S. Kim, X. J. Gu, G. Xia, and F. Adrian. 2007. Ba/F3 cells and their use in kinase drug discovery. Curr. Opin. Oncol. 19: 55-60.
35. Riedel, H., S. Massoglia, J. Schlessinger, and A. Ullrich. 1988. Ligand activation of overexpressed epidermal growth factor receptors transforms NIH 3T3 mouse fibroblasts. Proc. Natl. Acad. Sci. USA 85: 1477-1481.
36. Choi, S. H., J. M. Mendrola, and M. A. Lemmon. 2007. EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 26: 1567-1576.
37. Shtiegman, K., B. S. Kochupurakkal, Y. Zwang, G. Pines, A. Starr, A. Vexler, A. Citri, M. Katz, S. Lavi, Y. Ben-Basat, et al. 2007. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 26: 6968-6978.
38. Collins, M. K., J. Downward, A. Miyajima, K. Maruyama, K. Arai, and R. C. Mulligan. 1988. Transfer of functional EGF receptors to an IL3-dependent cell line. J. Cell. Physiol. 137: 293-298.
39. Weinstein, I. B. 2002. Cancer: addiction to oncogenes: the Achilles heal of cancer. Science 297: 63-64.
40. Matar, P., F. Rojo, R. Cassia, G. Moreno-Bueno, S. Di Cosimo, J. Tabernero, M. Guzman, S. Rodriguez, J. Arribas, J. Palacios, and J. Baselga. 2004. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res. 10: 6487-6501.
41. Mukohara, T., J. A. Engelman, N. H. Hanna, B. Y. Yeap, S. Kobayashi, N. Lindeman, B. Halmos, J. Pearlberg, Z. Tsuchihashi, L. C. Cantley, et al. 2005. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst. 97: 1185-1194.
42. Doody, J. F., Y. Wang, S. N. Patel, C. Joynes, S. P. Lee, J. Gerlak, R. L. Rolser, Y. Li, P. Steiner, R. Bassi, et al. 2007. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Mol. Cancer Ther. 6: 2642-2651.
43. Perez-Torres, M., M. Guix, A. Gonzalez, and C. L. Arteaga. 2006. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J. Biol. Chem. 281: 40183-40192.
44. Li, D., H. Ji, S. Zaghlul, K. McNamara, M. C. Liang, T. Shimamura, S. Kubo, M. Takahashi, L. R. Chirieac, R. F. Padera, et al. 2007. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J. Clin. Invest. 117: 346-352.
45. Zhang, W., M. Gordon, A. M. Schultheis, D. Y. Yang, F. Nagashima, M. Azuma, H. M. Chang, E. Borucka, G. Lurje, A. E. Sherrod, et al. 2007. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 25: 3712-3718.
46. Fan, Z., Y. Lu, X. Wu, and J. Mendelsohn. 1994. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem. 269: 27595-27602.
47. Van Cutsem, E., M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, J. L. Canon, J. L. Van Laethem, J. Maurel, G. Richardson, et al. 2007. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25: 1658-1664.
48. Tsuchihashi, Z., S. Khambata-Ford, N. Hanna, and P. A. Janne. 2005. Responsiveness to cetuximab without mutations in EGFR. N. Engl. J. Med. 353: 208-209.
49. Arteaga, C. L. 2004. Selecting the right patient for tumor therapy. Nat. Med. 10: 577-578.
50. Calvo, E., and J. Baselga. 2006. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J. Clin. Oncol. 24: 2158 -2163.